Reclassification of responses to induction chemotherapy by ELN 2022 criteria. The Sankey diagram shows comparison of response assessment to intensive blast-reduction therapy by PM criteria (left) and how this change when responses are reclassified by ELN 2022 criteria (right). Responses categorized as CR and CRi by PM criteria remain CR and CRi by ELN 2022 criteria, respectively. cMPN responses were reclassified as indicated to CR, CRi, MFLS, or no response/refractory (NR/R). SD and PD by PM criteria are NR/R by ELN 2022 criteria. MLFS, morphologic leukemia-free state.